Ironwood Pharmaceuticals, Inc. has reported its fourth quarter and full year 2025 financial results and recent business performance. In 2025, the company achieved total revenue of $296.2 million, with Linzess® (linaclotide) EUTRx demand growth reaching 11% year-over-year. The GAAP net income for 2025 was $24.0 million, and the adjusted EBITDA was $138.1 million.
The company reported total revenue of $47.7 million for the fourth quarter of 2025, compared to $90.5 million for the same period in 2024. Total costs and expenses for the fourth quarter of 2025 were $40.9 million, down from $59.1 million in the fourth quarter of 2024.
Linzess®, a key product for Ironwood, experienced a 27% decrease in U.S. net sales for the fourth quarter of 2025, amounting to $163.2 million compared to $223.0 million in the fourth quarter of 2024. The full year 2025 U.S. net sales for Linzess® were $864.5 million, showing a 6% decrease from $916.3 million in 2024.
Additionally, Ironwood expects full-year 2026 Linzess® U.S. net sales to range between $1.125 billion to $1.175 billion, with total revenues projected to be $450 million to $475 million. The company also anticipates adjusted EBITDA of over $300 million for 2026.
In the context of its product pipeline, Ironwood is advancing Apraglutide for the treatment of short bowel syndrome with intestinal failure (SBS-IF). The company finalized the key elements of the confirmatory phase 3 clinical trial design for Apraglutide in the fourth quarter of 2025, with site initiations expected to commence in the second quarter of 2026.
Ironwood's financial position improved, ending 2025 with $215 million in cash and cash equivalents, positioning the company well for 2026.
As a result of these announcements, the company's shares have moved -0.44% on the market, and are now trading at a price of $4.50. If you want to know more, read the company's complete 8-K report here.
